Swaminathan M, Ravandi F. Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?. haematol [Internet]. 2023Oct.1 [cited 2024Jul.19];108(10):2561-3. Available from: https://haematologica.org/article/view/haematol.2023.283120